Cryosite

Cryosite FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Cryosite (CTE.AX) as of Sep 27, 2026 is -364.16 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 78.45 % — a change of -564.19% (lower).

FCF Conversion

-364.16 %

YoY

-564.19%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Cryosite is 2026 -364.16 % . FCF Conversion Rate (FCF/EBITDA) of Cryosite was 2025 78.45 % . It decreases by -564.19% lower compared to the previous year.

The Cryosite FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2019
119.20 AUD
Jan 1, 2020
26.79 AUD
Jan 1, 2021
12.27 AUD
Jan 1, 2022
119.64 AUD
Jan 1, 2023
78.57 AUD
Jan 1, 2024
124.51 AUD
Jan 1, 2025
78.45 AUD
Jan 1, 2026
-364.16 AUD
The Cryosite FCF Conversion history
YEARFCF ConversionYoY
-364.16 %-564.19%
78.45 %-36.99%
124.51 %+58.48%
78.57 %-34.33%
119.64 %+875.06%
12.27 %-54.20%
26.79 %-77.53%
119.20 %-34.11%
180.91 %-117.76%
-1,018.93 %-2,750.79%
38.44 %-83.42%
231.79 %+0.06%
231.64 %—
Access this data via the Eulerpool API

Cryosite Stock analysis

What does Cryosite do? Cryosite Ltd was founded in Australia in 1999 and has since become a leading provider of services in the field of biological sample storage. The company specializes in the storage of blood, bone marrow, tissue, and other biological samples. Based in Sydney, Cryosite Ltd operates branches throughout Australia and is increasingly expanding into international business. Cryosite Ltd's business model is based on providing secure and reliable storage solutions for biological samples. This includes the collection, processing, and storage of biological samples, as well as their transportation and traceability. Cryosite Ltd offers its customers a comprehensive range of services to facilitate the storage and shipment of biological samples. This includes the development of customized archiving solutions tailored to individual needs. The company's various divisions include archiving solutions, clinical trials, stem cell therapy, biobanking, and blood banks. Cryosite Ltd's archiving solutions involve the setup, maintenance, and monitoring of biological samples in engraved tubes and boxes. The company offers a variety of cryopreservation systems to ensure that samples are stored under optimal conditions and can be retrieved within a specified timeframe. Additionally, the company also provides digital archiving solutions that enable efficient management and retrieval of stored data. Cryosite Ltd is also involved in clinical trials by assisting companies in conducting clinical studies. The company provides the necessary logistics and sample management to ensure that samples are properly processed, stored, and returned. It also provides comprehensive documentation to ensure the highest compliance standards. In the field of stem cell therapy, Cryosite Ltd offers a wide range of services that enable companies and researchers to store and process stem cells under optimal conditions. The company specializes in providing a wide range of application-oriented solutions and is a leader in the industry in supporting customers in the use of these technologies to enhance diagnostic and therapeutic discoveries. In the field of biobanking, Cryosite Ltd offers a comprehensive range of services to research institutes and organizations. Biobanking services include the setup, storage, monitoring, and tracking of biological samples for future research purposes. The company also offers services for the biobanking of clinical samples for disease diagnosis and evaluation. The company also operates blood banks that focus on blood donation and storage of blood products for efficient availability to patients. It offers a wide range of blood bank products and services to ensure effective blood supply for patients. Cryosite Ltd is committed to providing its customers with the highest standards in the storage and handling of blood products. In summary, Cryosite Ltd is a leading provider of storage and processing services for biological samples. The company has a long history of providing solutions for a wide range of applications in medical research and the medical industry. It strives to meet the highest standards and ensure that all samples are processed and stored efficiently and safely. Cryosite Ltd stays up to date with the latest technology and advanced processes to handle samples with maximum efficiency and quality. Cryosite is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cryosite stock

FCF Conversion Rate (FCF/EBITDA) of Cryosite is -364.16 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of Cryosite changed from 78.45 % to -364.16 %, representing a -564.19% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Cryosite since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Cryosite with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

Cash Flow — Cryosite

All Key Metrics — Cryosite